Sanofi (NASDAQ:SNY) Upgraded to Strong-Buy at Sanford C. Bernstein

Sanofi (NASDAQ:SNY) was upgraded by equities research analysts at Sanford C. Bernstein to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

SNY has been the topic of several other research reports. Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.50.

Sanofi Price Performance

NASDAQ SNY opened at $44.60 on Thursday. The business’s fifty day moving average is $46.46 and its 200 day moving average is $48.05. Sanofi has a fifty-two week low of $43.32 and a fifty-two week high of $57.60. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The company has a market capitalization of $108.78 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.45.

Institutional Trading of Sanofi

Institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC lifted its position in shares of Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the last quarter. Waterfront Wealth Inc. boosted its stake in shares of Sanofi by 0.4% during the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after purchasing an additional 214 shares during the period. Savant Capital LLC grew its holdings in shares of Sanofi by 2.7% in the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after purchasing an additional 225 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in Sanofi by 2.3% in the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after buying an additional 226 shares during the period. Finally, Wesbanco Bank Inc. increased its stake in Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after buying an additional 230 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.